JP2024542682A5 - - Google Patents

Info

Publication number
JP2024542682A5
JP2024542682A5 JP2024532418A JP2024532418A JP2024542682A5 JP 2024542682 A5 JP2024542682 A5 JP 2024542682A5 JP 2024532418 A JP2024532418 A JP 2024532418A JP 2024532418 A JP2024532418 A JP 2024532418A JP 2024542682 A5 JP2024542682 A5 JP 2024542682A5
Authority
JP
Japan
Prior art keywords
tcr
dose
fusion molecule
range
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024532418A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024542682A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/083952 external-priority patent/WO2023099622A1/en
Publication of JP2024542682A publication Critical patent/JP2024542682A/ja
Publication of JP2024542682A5 publication Critical patent/JP2024542682A5/ja
Pending legal-status Critical Current

Links

JP2024532418A 2021-12-01 2022-11-30 治療 Pending JP2024542682A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163285044P 2021-12-01 2021-12-01
US63/285,044 2021-12-01
US202263374222P 2022-08-31 2022-08-31
US63/374,222 2022-08-31
PCT/EP2022/083952 WO2023099622A1 (en) 2021-12-01 2022-11-30 Treatment

Publications (2)

Publication Number Publication Date
JP2024542682A JP2024542682A (ja) 2024-11-15
JP2024542682A5 true JP2024542682A5 (cg-RX-API-DMAC10.html) 2025-12-08

Family

ID=84688213

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024532418A Pending JP2024542682A (ja) 2021-12-01 2022-11-30 治療

Country Status (9)

Country Link
US (1) US20250333504A1 (cg-RX-API-DMAC10.html)
EP (1) EP4441096A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024542682A (cg-RX-API-DMAC10.html)
KR (1) KR20240114759A (cg-RX-API-DMAC10.html)
AU (1) AU2022402322A1 (cg-RX-API-DMAC10.html)
IL (1) IL312981A (cg-RX-API-DMAC10.html)
MX (1) MX2024006799A (cg-RX-API-DMAC10.html)
TW (1) TW202330589A (cg-RX-API-DMAC10.html)
WO (1) WO2023099622A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202519257A (zh) 2023-08-01 2025-05-16 英商英美偌科有限公司 治療皮膚黑色素瘤之方法
TW202544042A (zh) 2024-03-13 2025-11-16 英商英美偌科有限公司 治療prame陽性癌症之方法
WO2025224692A1 (en) 2024-04-25 2025-10-30 Immunocore Limited Method of treating cancer using a gene expression signature

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1421115E (pt) 2001-08-31 2005-07-29 Avidex Ltd Receptor de celulas t soluvel
GB201223172D0 (en) 2012-12-21 2013-02-06 Immunocore Ltd Method
JP7599819B2 (ja) * 2016-06-02 2024-12-16 イムノコア リミテッド gp100特異的TCR-抗CD3 scFv融合タンパク質の投薬レジメン
GB201709866D0 (en) 2017-06-20 2017-08-02 Immunocore Ltd T cell receptors

Similar Documents

Publication Publication Date Title
Huppert et al. Transarterial chemoembolization of liver metastases in patients with uveal melanoma
JP2025016606A5 (cg-RX-API-DMAC10.html)
JP2024518947A5 (cg-RX-API-DMAC10.html)
JP2017537105A5 (cg-RX-API-DMAC10.html)
JP2020521797A5 (cg-RX-API-DMAC10.html)
JP2020517658A5 (cg-RX-API-DMAC10.html)
JP2021514661A5 (cg-RX-API-DMAC10.html)
CN114746117A (zh) 抗dll3药剂的给药方案
US20230303678A1 (en) Methods for treatment of subjects with plaque psoriasis of the scalp
JP2021514354A5 (cg-RX-API-DMAC10.html)
JP2024540275A5 (cg-RX-API-DMAC10.html)
JP2002507571A (ja) アントラサイクリン誘導体とカンプトテシン誘導体の相乗組合せを含有する抗腫瘍組成物
JP2025508786A5 (cg-RX-API-DMAC10.html)
JP2022523530A5 (cg-RX-API-DMAC10.html)
WO2023061472A1 (zh) 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途
RU2010151660A (ru) Способы лечения множественной миеломы
JP2023545084A5 (cg-RX-API-DMAC10.html)
RU2009118962A (ru) Применение антагонистов il-1 для лечения подагры и псевдоподагры
WO2020243603A1 (en) Dosing of bispecific t cell engager
JP2024028756A5 (cg-RX-API-DMAC10.html)
JP6034314B2 (ja) B細胞リンパ腫の治療における放射線標識化抗cd20抗体を使用する組合わせ治療
JP2022513029A5 (cg-RX-API-DMAC10.html)
WO2024183817A1 (zh) 抗cd20抗体药物偶联物在制备治疗套细胞淋巴瘤的药物中的用途
TW202535468A (zh) 使用免疫檢查點抑制劑抗體治療癌症之方法和組合
WO2020236668A1 (en) Leukadherin-1 alone or in combination for use in the treatment of cancer